Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. (JNCE) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · JNCE · as of Jun 9, 2026
Key Statistics
Explore Jounce Therapeutics, Inc. Data
jnce stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 10 · Buy rate: 50.0%
Competitors & Peers
jnce competitorsJNCE
AADI
BLI
CYT
DBTX
HLVXStock Performance
Full HistoryAbout Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. is an immunotherapy firm currently in the clinical development phase, dedicated to discovering and advancing new cancer treatments. A key asset in its pipeline is vopratelima…
what is jounce therapeutics, inc. · jnce stock overview · jounce therapeutics, inc. company profile · who is jounce therapeutics, inc. ceo · jnce NASDAQ · jounce therapeutics, inc. headquarters · jounce therapeutics, inc. business segments
About Stock Overview & Key Data
Jounce Therapeutics, Inc. (JNCE) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jan 26, 2017. As of the latest trading session, JNCE stock price is $1.88, with a market capitalization of $99.0M. The stock has returned -49.19% over the past 12 months and +72.48% year-to-date.
According to 10 Wall Street analysts, the consensus rating for Jounce Therapeutics, Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2022, Jounce Therapeutics, Inc. reported revenue of $82.0M and net income of -$50.9M. For detailed data — including Jounce Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Jounce Therapeutics, Inc. (JNCE) stock price is $1.88. The stock is traded on NASDAQ under the ticker symbol JNCE. The 52-week range is $0.58 – $5.37.